Bristol Projects Opdivo Sales Will Grow Again In 2021
With new Opdivo/Yervoy combination data in first-line lung cancer, the company expects the PD-1 inhibitor’s growth to go from flat to rising in 2021. Bristol’s and Celgene’s third quarter earnings exceeded expectations and their merger is on track to close this year.
You may also be interested in...
Recent launches and products acquired with Celgene are helping BMS grow, CEO Caforio said, while Opdivo is moving toward resuming growth thanks to first-line NSCLC and other factors.
More lung cancer patients treated with neoadjuvant Opdivo plus chemotherapy had a pathologic complete response than those who received chemo alone. BMS will discuss the results with regulators.
Bristol Myers Squibb brought in $500m from customers that overbought in case of drug shortages, but first quarter sales still grew 8% excluding those purchases and BMS projects growth through 2021.